Pasithea Therapeutics (KTTA) Common Equity (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Common Equity for 4 consecutive years, with $17.8 million as the latest value for Q3 2024.
- Quarterly Common Equity fell 37.22% to $17.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Sep 2024, down 37.22% year-over-year, with the annual reading at $23.4 million for FY2023, 44.94% down from the prior year.
- Common Equity hit $17.8 million in Q3 2024 for Pasithea Therapeutics, up from $16.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $51.4 million in Q4 2021 to a low of $470078.0 in Q2 2021.
- Historically, Common Equity has averaged $29.3 million across 4 years, with a median of $28.4 million in 2023.
- Biggest five-year swings in Common Equity: skyrocketed 10817.73% in 2022 and later tumbled 54.55% in 2024.
- Year by year, Common Equity stood at $51.4 million in 2021, then decreased by 17.35% to $42.5 million in 2022, then crashed by 44.94% to $23.4 million in 2023, then fell by 23.87% to $17.8 million in 2024.
- Business Quant data shows Common Equity for KTTA at $17.8 million in Q3 2024, $16.2 million in Q2 2024, and $19.9 million in Q1 2024.